Jeffrey S. Armstrong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jeffrey S. Armstrong has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Hongyuan Yang
Department of Integrative Biology and Pharmacology, University of Texas Health Science Center at Houston
2 shared publications Matthew Whiteman
Department of Biochemistry, National University of Singapore, Singapore 117597, Singapore
2 shared publicationsC. Lu
Department of Biochemistry, National University of Singapore, Singapore
1 shared publicationDean P. Jones
Department of Medicine, Faculty of Medicine, Emory University, Atlanta, USA
1 shared publicationI. F. Bambang
Department of Biochemistry, National University of Singapore, Singapore
1 shared publicationM. Whiteman
Peninsula Medical School, Universities of Exeter and Plymouth, St Luke’s Campus, Exeter, UK
1 shared publication
Latest Publications
- 10 March 2008
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 10 (4) , 347-349
Resveratrol blocks high glucose–induced mitochondrial reactive oxygen species production in bovine aortic endothelial cells: role of phase 2 enzyme induction?
- 10 March 2008
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 10 (4) , 347-349
Resveratrol blocks high glucose–induced mitochondrial reactive oxygen species production in bovine aortic endothelial cells: role of phase 2 enzyme induction?
- 1 August 2007
- Published by Wiley in British Journal of Pharmacology
- Vol. 151 (8) , 1154-1165
Mitochondrial Medicine: Pharmacological targeting of mitochondria in disease
Mitochondria play a central role in cell life and death and are known to be important in a wide range of diseases including the cancer, diabetes, cardiovascular disease, and the age‐related neurodegenerative diseases. The unique structural and functional characteristics of mitochondria enable the selective targeting of drugs designed to modulate the function of this organelle for therapeutic gain. This review discusses mitochondrial drug targeting strategies and a variety of novel mitochondrial drug targets including the electron transport chain, mitochondrial permeability transition, Bcl‐2 family proteins and mitochondrial DNA. Mitochondrial drug‐targeting strategies will open up avenues for manipulating mitochondrial functions and allow for selective protection or eradication of cells for therapeutic gain in a variety of diseases.British Journal of Pharmacology (2007) 151, 1154–1165; doi:10.1038/sj.bjp.0707288
- 1 August 2007
- Published by Wiley in British Journal of Pharmacology
- Vol. 151 (8) , 1154-1165
Mitochondrial Medicine: Pharmacological targeting of mitochondria in disease
Mitochondria play a central role in cell life and death and are known to be important in a wide range of diseases including the cancer, diabetes, cardiovascular disease, and the age‐related neurodegenerative diseases. The unique structural and functional characteristics of mitochondria enable the selective targeting of drugs designed to modulate the function of this organelle for therapeutic gain. This review discusses mitochondrial drug targeting strategies and a variety of novel mitochondrial drug targets including the electron transport chain, mitochondrial permeability transition, Bcl‐2 family proteins and mitochondrial DNA. Mitochondrial drug‐targeting strategies will open up avenues for manipulating mitochondrial functions and allow for selective protection or eradication of cells for therapeutic gain in a variety of diseases.British Journal of Pharmacology (2007) 151, 1154–1165; doi:10.1038/sj.bjp.0707288
- 1 October 2006
- Published by Elsevier in Mitochondrion
- Vol. 6 (5) , 225-234
The role of the mitochondrial permeability transition in cell death
- 1 October 2006
- Published by Elsevier in Mitochondrion
- Vol. 6 (5) , 225-234
The role of the mitochondrial permeability transition in cell death
Mitochondrial membrane permeabilization: the sine qua non for cell death
Mitochondria are essential for maintaining cell life but they also play a role in regulating cell death, which occurs when their membranes become permeabilized. Mitochondria possess two distinct membrane systems including an outer membrane in close communication with the cytosol and an inner membrane involved in energy transduction. Outer membrane permeabilization is regulated by Bcl‐2 family proteins, which control the release of proteins from the mitochondrial intermembrane space; these proteins then activate apoptosis. Inner membrane permeabilization is regulated by the mitochondrial permeability transition (MPT), which is activated by calcium and oxidative stress and leads to bioenergetic failure and necrosis. The purpose of this review is to discuss the biochemical mechanisms regulating mitochondrial membrane permeabilization; this is crucial to our understanding of the role of cell death in diseases such as cancer and the neurodegenerative diseases. BioEssays 28: 253–260, 2006.
Mitochondrial membrane permeabilization: the sine qua non for cell death
Mitochondria are essential for maintaining cell life but they also play a role in regulating cell death, which occurs when their membranes become permeabilized. Mitochondria possess two distinct membrane systems including an outer membrane in close communication with the cytosol and an inner membrane involved in energy transduction. Outer membrane permeabilization is regulated by Bcl‐2 family proteins, which control the release of proteins from the mitochondrial intermembrane space; these proteins then activate apoptosis. Inner membrane permeabilization is regulated by the mitochondrial permeability transition (MPT), which is activated by calcium and oxidative stress and leads to bioenergetic failure and necrosis. The purpose of this review is to discuss the biochemical mechanisms regulating mitochondrial membrane permeabilization; this is crucial to our understanding of the role of cell death in diseases such as cancer and the neurodegenerative diseases. BioEssays 28: 253–260, 2006.
- 1 February 2006
- Published by Wiley in British Journal of Pharmacology
- Vol. 147 (3) , 239-248
Mitochondria: a target for cancer therapy
Mitochondria, the cells powerhouses, are essential for maintaining cell life, and they also play a major role in regulating cell death, which occurs upon permeabilization of their membranes. Once mitochondrial membrane permeabilization (MMP) occurs, cells die either by apoptosis or necrosis. Key factors regulating MMP include calcium, the cellular redox status (including levels of reactive oxygen species) and the mobilization and targeting to mitochondria of Bcl‐2 family members. Contemporary approaches to targeting mitochondria in cancer therapy use strategies that either modulate the action of Bcl‐2 family members at the mitochondrial outer membrane or use specific agents that target the mitochondrial inner membrane and the mitochondrial permeability transition (PT) pore. The aim of this review is to describe the major mechanisms regulating MMP and to discuss, with examples, mitochondrial targeting strategies for potential use in cancer therapy.British Journal of Pharmacology (2006) 147, 239–248. doi:10.1038/sj.bjp.0706556
- 1 February 2006
- Published by Wiley in British Journal of Pharmacology
- Vol. 147 (3) , 239-248
Mitochondria: a target for cancer therapy
Mitochondria, the cells powerhouses, are essential for maintaining cell life, and they also play a major role in regulating cell death, which occurs upon permeabilization of their membranes. Once mitochondrial membrane permeabilization (MMP) occurs, cells die either by apoptosis or necrosis. Key factors regulating MMP include calcium, the cellular redox status (including levels of reactive oxygen species) and the mobilization and targeting to mitochondria of Bcl‐2 family members. Contemporary approaches to targeting mitochondria in cancer therapy use strategies that either modulate the action of Bcl‐2 family members at the mitochondrial outer membrane or use specific agents that target the mitochondrial inner membrane and the mitochondrial permeability transition (PT) pore. The aim of this review is to describe the major mechanisms regulating MMP and to discuss, with examples, mitochondrial targeting strategies for potential use in cancer therapy.British Journal of Pharmacology (2006) 147, 239–248. doi:10.1038/sj.bjp.0706556
- Open Access
- 1 November 2004
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 279 (48) , 50420-50428
Cytochrome bc1 Regulates the Mitochondrial Permeability Transition by Two Distinct Pathways
- 1 November 2004
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 279 (48) , 50420-50428
Open AccessCytochrome bc1 Regulates the Mitochondrial Permeability Transition by Two Distinct Pathways
The redox regulation of intermediary metabolism by a superoxide–aconitase rheostat
In this article, we discuss a hypothesis to explain the preferential synthesis of the superoxide sensitive form of aconitase in mitochondria and the phenotype observed in manganese superoxide dismutase mutant mice, which show a gross over accumulation of stored fat in liver. The model proposes that intermediary metabolism is redox regulated by mitochondrial superoxide generated during mitochondrial respiration. This regulates the level of reducing equivalents (NADH) entering the electron transport chain (ETC) through the reversible inactivation of mitochondrial aconitase. This control mechanism has a dual function; firstly, it regulates levels of superoxide generated by the ETC and, secondly, it fine‐tunes metabolism by channeling citrate either for the production of NADH for energy metabolism or diverting it for the synthesis of fats. In this setting, the mitochondrial redox state influences metabolic decisions via a superoxide–aconitase rheostat. BioEssays 26:894–900, 2004.
The redox regulation of intermediary metabolism by a superoxide–aconitase rheostat
In this article, we discuss a hypothesis to explain the preferential synthesis of the superoxide sensitive form of aconitase in mitochondria and the phenotype observed in manganese superoxide dismutase mutant mice, which show a gross over accumulation of stored fat in liver. The model proposes that intermediary metabolism is redox regulated by mitochondrial superoxide generated during mitochondrial respiration. This regulates the level of reducing equivalents (NADH) entering the electron transport chain (ETC) through the reversible inactivation of mitochondrial aconitase. This control mechanism has a dual function; firstly, it regulates levels of superoxide generated by the ETC and, secondly, it fine‐tunes metabolism by channeling citrate either for the production of NADH for energy metabolism or diverting it for the synthesis of fats. In this setting, the mitochondrial redox state influences metabolic decisions via a superoxide–aconitase rheostat. BioEssays 26:894–900, 2004.